Bicyclic CX3CR1 receptor agonists

US11958839B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11958839-B2
Application numberUS-202117481653-A
CountryUS
Kind codeB2
Filing dateSep 22, 2021
Priority dateJul 23, 2019
Publication dateApr 16, 2024
Grant dateApr 16, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of treatment of a neurodegenerative disorder chosen from Alzheimer's disease, Lewy body dementia, fronto-temporal dementia, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, HIV-induced neuroinflammation, essential tremors, and Charcot-Marie-Tooth neuropathy comprising the administration of a therapeutically effective amount of a compound of the following formula (I) or a stereoisomer thereof, or a salt thereof, to a subject in need thereof, wherein: n is an integer between 1 and 4, forming a 6-10-membered cycloalkyl; A is chosen from phenyl and heteroaryl, optionally substituted with one or more C 1 -C 3 alkyl substituents; R 1 is chosen from hydrogen and C 1 -C 3 alkyl; R 2 and R 3 are independently chosen from hydrogen, phenyl, and C 1 -C 6 alkyl; or R 2 and R 3 are joined together via a group Y, wherein R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 7 cycloalkyl or C 3 -C 7 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl; or the C 3 -C 7 cycloalkyl or C 3 -C 7 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl; Y is chosen from C and O; R 4 is chosen from R 5 and R 6 are each independently C 1 -C 6 alkyl; R 7 , R 8 , R 9 , and R 10 are independently chosen from hydrogen and hydroxyl, or is independently chosen from C 1 -C 6 alkyl and C 1 -C 6 alkyloxy, either of which is optionally substituted with methoxy; p is 1 or 2; and X is chosen from C, O, or NR 11 where R 11 is hydrogen or C 1 -C 3 alkyl; with the proviso that if A is thiophene, n is 2 or 3, R 1 is hydrogen, and R 4 is then either R 5 and R 6 are not both methyl, and/or R 2 and R 3 are not both methyl, and further provided that if A is thiophene, n is 2 or 3, R 1 is hydrogen, and R 4 is then R 2 and R 3 are not hydrogen. 2. The method as recited in claim 1 , wherein A is thiophene. 3. The method as recited in claim 1 , wherein R 1 is chosen from hydrogen and methyl. 4. The method as recited in claim 3 , wherein R 2 and R 3 are independently chosen from hydrogen, methyl, ethyl, and phenyl; or R 2 and R 3 are joined together via a group Y, wherein R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 6 cycloalkyl or heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 7 cycloalkyl or C 3 -C 7 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl. 5. The method as recited in claim 4 , wherein R 2 and R 3 are independently chosen from hydrogen, methyl, ethyl, and phenyl. 6. The method as recited in claim 4 , wherein R 2 and R 3 are joined together via a group Y, wherein R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl. 7. The method as recited in claim 4 , wherein R 5 and R 6 are each independently C 1 -C 3 alkyl. 8. The method as recited in claim 4 , wherein R 7 , R 8 , R 9 , and R 10 are independently hydrogen, hydroxyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, optionally substituted with methoxy. 9. The method as recited in claim 4 , wherein X is chosen from C, O, or NH. 10. The method as recited in claim 1 , wherein: n is a number between 1 and 4, forming a 6-10-membered cycloalkyl; A is thiophene; R 1 is chosen from hydrogen and methyl; R 2 and R 3 are independently chosen from hydrogen, methyl, ethyl, and phenyl; or R 2 and R 3 are joined together via a group Y, wherein R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl; Y is chosen from C and O; R 4 is chosen from R 5 and R 6 are independently C 1 -C 3 alkyl; R 7 , R 8 , R 9 , and R 10 are independently chosen from hydrogen, hydroxyl, C 1 -C 3 alkyl, and C 1 -C 3 alkoxy, optionally substituted with methoxy; p is 1 or 2; and X is chosen from C, O, or NR 11 ; and R 11 is C 1 -C 3 alkyl. 11. The method as recited in claim 1 , wherein A is 3-methylthiophene. 12. The method as recited in claim 11 , wherein R 1 is chosen from hydrogen and methyl. 13. The method as recited in claim 11 , wherein R 2 and R 3 are independently chosen from hydrogen, methyl, ethyl, and phenyl; or R 2 and R 3 are joined together via a group Y, wherein R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms a C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl. 14. The method as recited in claim 11 , wherein R 2 and R 3 are independently chosen from hydrogen, methyl, ethyl, and phenyl. 15. The method as recited in claim 11 , wherein R 2 and R 3 are joined together via a group Y, wherein R 2 —Y—R 3 , together with the carbon to which R 2 and R 3 attach, forms C 3 -C 6 cycloalkyl or heterocycloalkyl, either of which is optionally substituted with one or more substituents chosen from hydroxyl, fluorine, and methyl; or the C 3 -C 6 cycloalkyl or C 3 -C 6 heterocycloalkyl is fused with a phenyl ring which is optionally substituted with one or more substituents chosen from hydroxyl, halogen, and C 1 -C 6 alkyl. 16. The method as recited in claim 11 , wherein either: R 2 is hydrogen and R 3 is methyl or phenyl; or R 2 and R 3 are both methyl or both ethyl. 17. The method as recited in claim 16 , wherein R 2 is hydrogen and R 3 is methyl or phenyl. 18. The method as recited in claim 16 , wherein R 2 and R 3 are both methyl or ethyl. 19. The method as recited in claim 11 , wherein Y is chosen from C and O; and R 2 and R 3 are joined together via the group Y, wherein the group R 2 —Y—R 3 , together wit

Assignees

Inventors

Classifications

  • C07D409/14Primary

    containing three or more hetero rings · CPC title

  • with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom · CPC title

  • C07D333/78Primary

    condensed with rings other than six-membered or with ring systems containing such rings · CPC title

  • C07D409/12Primary

    linked by a chain containing hetero atoms as chain links · CPC title

  • Seven-membered rings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11958839B2 cover?
Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.
Who is the assignee on this patent?
Univ Texas, Golgi Neurosciences S R L
What technology area does this patent fall under?
Primary CPC classification C07D409/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).